The Growing Role of Oncology Billing Services in Precision Cancer Care

Cancer treatment has undoubtedly changed significantly over the years with research and treatments. Additionally, with the development of molecular profiling, genomic testing, targeted therapies, and immunotherapies; all can help clinicians ensure tailored treatment for precision oncology services.

However, clinical advances must be supported by a revenue cycle capable of managing complex coverage, authorization, coding, and reimbursement requirements. As one treatment plan can touch molecular testing, payer-specific coverage rules, prior authorization, niche coding, and reimbursement logic that changes depending on who is holding the insurance card. And this is exactly the mess oncology billing services exist to untangle.

All about Precision Oncology services:

The use of molecular, genomic, and other patient-specific information as well as characteristics of the tumor and inherited genetic variants to support diagnosis, prognosis, treatment selection, and clinical trial eligibility caters to precision oncology treatments for cancer patients.

Depending on the cancer type and clinical indication, precision oncology may involve:

While none of this is just confirming yes to cancer. It is about what the specific tumor is doing at a molecular level and letting that steer the treatment. Also, ASCO has pointed to the growing role of tumor genomic sequencing in advanced and metastatic disease, particularly where an actionable genomic alteration can actually change the treatment plan. While this is a clinical win, it is also a billing headache waiting to happen.

Why Precision Oncology Creates a Billing Problem

Oncology billing was already hard before any of this. Add precision medicine and you are stacking clinical complexity, coding issues, authorization challenges, and reimbursement hurdles, all on top of each other.

Strip the patient journey down to its bones, and it is actually pretty simple on paper: diagnose, test for biomarkers, run the genomic analysis, pick a treatment, clear prior authorization, give the medication, submit the claim, wait for the payer to weigh in; then either get paid or get denied.

Here is the tricky part. A test that is clinically necessary and a therapy that is exactly right for the patient can still get denied because:

Nobody caught that prior authorization was required

• The CPT, HCPCS, or molecular pathology code was wrong
• The documentation did not clearly justify medical necessity
• A modifier was missing, or the claim contradicted itself
• The payer’s coverage policy quietly changed
• The service was billed under the wrong benefit; medical instead of pharmacy, or the opposite
• The appeal went out without the paperwork needed to win it

None of this is a typo problem, it is a structural one. Generic medical billing was not built to carry this much clinical nuance, which is exactly why oncology revenue cycle management has to be its own discipline.

The Real Job of Oncology Billing Services in Precision Cancer Care

Think of a good oncology billing team as the thing standing between the practice, the lab, the payer, and the patient; quietly making sure none of those parties are working off different information.

Submitting the claim is not enough. The job is building a claim that is accurate, backed by documentation, coded right, aligned with what the payer wants to see, and built to get paid the first time.

1. Insurance Verification Has to Go Deeper

Checking coverage cannot just mean “yes, they have insurance.” In precision oncology, billing teams need to know if this plan covers this molecular test, or the prescribed genomic panel, the targeted therapy. Such precision while verifying insurance eligibility is necessary because coverage for genetic and genomic testing swings wildly between Medicare, Medicaid, and commercial plans.

Before anything happens, an expert oncology billing services provider reviews:

• Patient eligibility and benefits
• Whether molecular/genetic testing is covered at all
• Medical-necessity criteria
• Prior authorization requirements
• Lab network restrictions
• Specialty-drug coverage
• Medical vs. pharmacy benefit
• What the patient will owe out of pocket

Skip this step and you find out the hard way after the test is already done that the payer never covered it under these circumstances.

2. Prior Authorization: Oncology’s Biggest Bottleneck

If there is one thing oncologists universally feel negatively about, it is prior authorization. Starting from molecular testing to oncology specialty drugs; payers can require prior authorization and each payer is likely to come with unique requirements and documentation standards for the same.

And the numbers back up the frustration. In ASCO’s 2022 member survey, 96% of respondents reported that prior authorization had delayed treatment for patients, while 80% reported patient harm involving disease progression. These results describe respondents’ reported experiences, not the percentage of all authorization requests that caused those outcomes. This is not only paperwork inconvenience but indicates actual patient harm.

A solid oncology billing services partner handles this by:

• Figuring out whether authorization is even required
• Knowing exactly what documentation the payer wants
• Making sure the coding matches the records supporting it
• Submitting it, then actually tracking it
• Watching expiration dates so nothing lapses mid-treatment
• Double-checking that what is on the claim matches what was approved

3. Molecular Testing and NGS Billing Are Not Standard Lab Billing

Do not bill molecular testing like you would bill a basic lab panel. It is not the same. Molecular testing may involve genomic sequencing procedure codes, Tier 1 or Tier 2 molecular pathology codes, multianalyte assay codes, or proprietary laboratory analysis codes. The selected code must represent the test actually performed and comply with current CPT instructions and payer policy. Individual gene codes should not automatically be stacked when a panel-specific code appropriately describes the service. While NGS makes it worse, since a single panel might be evaluating dozens of genes or biomarkers at once.

And the whole billing process must hold together as one chain; clinical indication, test performed, applicable code, diagnosis, medical necessity, payer policy, claim. Every link has to line up with the next or the reimbursement falls apart. Break one link and the whole claim is vulnerable.

An expert oncology billing services team catches things like:

• Wrong or missing codes
• Medical necessity that is not clearly established
• Documentation gaps
• Coverage restrictions nobody flagged
• Authorization that was never obtained
• Diagnosis codes that do not match the service billed
• Lab billing inconsistencies

4. Clinical Documentation Is the Foundation

Everything above depends on this. A claim can have the right code sitting right on it and still get denied because the chart does not clearly say why the service was necessary. Depending on the service and payer policy, the treating provider’s documentation may need to include relevant clinical information such as:

• Cancer type and primary site
• Histology and stage
• Metastatic status
• Pathology and imaging findings
• Biomarker or genomic results
• What treatments came before
• How the patient responded or progressed
• The actual clinical reasoning behind the choice

Billing teams cannot write that documentation for you; that is not their job. But an expert oncology billing services team makes sure to identify when the same denial keeps happening for the same reason and tell Mbefore it happens again.

5. Drug Billing: Where Precision Treatment Meets Real Financial Risk

Targeted therapies and immunotherapies are not cheap, and one billing mistake on a high-cost drug hurts a lot more than a typo on a routine claim, you are looking at:

• HCPCS drug codes,
• CPT administration codes,
• Unit counts,
• NDCs where they apply,
• Drug wastage,
• JW/JZ modifiers,
• Buy-and-bill logistics,
• Medical vs. pharmacy benefit questions,
• White or brown bagging, and
• Site-of-care rules; all potentially in play on a single treatment.

For instance, under buy-and-bill, the practice is literally buying the drug, holding it, administering it, then trying to get paid back. That means the revenue cycle must track the whole thing; acquisition, inventory, administration, documentation, coding, the claim, and the payment; as one continuous thread. Drop it anywhere and money disappears. An expert oncology billing services provider can ensure that does not happen.

6. Denial Management Should Be Driven by Data

Most oncology practices approach denials in a game of whack-a-mole fashion; something happens, somebody addresses it, then everybody gets back to business. This is not denial management; it is simply quicker reaction time.

But what we should ask is: why is this continuing in the first place?

A specialist oncology billing services company categorizes the denials into payer-related, diagnosis-related, code-related, drug-related, test-related, authorization problems, documentation issues, eligibility issues, filing deadlines, contract disagreements; then identifies the hidden pattern underneath. The reason why one payer denies the same molecular test for medical necessity over and over again is not resolved with more appeals but with identifying the underlying cause of it.

7. Precision Billing Runs on Payer-Specific Knowledge

There is no single rulebook here. Medicare requirements, Medicare Administrative Contractor policies, state Medicaid programs, and commercial payer rules may have completely different requirements for molecular testing, genomic sequencing, specialty drugs, and prior authorization. Additionally, coverage, coding, authorization, and documentation requirements can change, making regular policy monitoring essential.

Tracking that internally, across every payer a practice deals with, gets unmanageable fast. A specialized oncology billing services partner builds that knowledge directly into the workflow:

• Coverage policies
• Medical-necessity criteria
• Authorization rules
• Coding requirements
• Lab restrictions
• Drug reimbursement policies
• Documentation standards
• Appeal procedures
• Contract rates

The same exact service can be reimbursed completely differently depending on whose insurance card the patient hands you. Thus, knowing the code is only half the job, but understanding how that code actually behaves inside each payer’s system is where the real value is.

Key KPIs for Measuring Precision Oncology Billing Performance:

If nobody is tracking these, nobody actually knows if the billing is working. They are just hoping. So, choose an oncology billing partner based on these metrics.

Read More:

Essential KPIs for Better Medical Billing for Oncology 

Why Practices Choose SunKnowledge

Oncology billing is not something you learn on the fly; the codes are too specific, the drugs too expensive, the payers too unforgiving. SunKnowledge has spent 15+ years doing nothing but this: J-code sequencing, chemotherapy and radiation oncology coding, pre-authorization for high-cost drugs, and end-to-end RCM from eligibility checks through final collections. Our certified coders and A/R team back it up with a 97% first-pass acceptance rate and real traction on A/R sitting past 90 days, and all on a flat-fee model, so there is no pricing surprise waiting for you later.
Struggling to manage your oncology billing services?  We have extensive experience in healthcare revenue cycle management. If denials keep piling up or your team is stretched thin, book a no-commitment call with SunKnowledge and see what precision billing looks like when it is working.